Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2014010183
pages 91-102

Tumor Plasticity Interferes with Anti-Tumor Immunity

Salem Chouaib
Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates; INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, EPHE, Faculty de Médecine University Paris-Sud, University Paris-Saclay, Villejuif F-94805, France
Bassam Janji
Laboratory of Experimental Hemato-Oncology, Department of Oncology, Public Research Center for Health (CRP-Sante), L-1526 Luxembourg City, Luxembourg
Andres Tittarelli
Institut National de la Sante et de la Recherche Medicale (INSERM U753); Institut Federatif de Recherche 54 (IFR54); Institut de cancerologie Gustave Roussy. F-94800 Villejuif, France
Alexander Eggermont
Institut National de la Sante et de la Recherche Medicale (INSERM U753); Institut Federatif de Recherche 54 (IFR54); Institut de cancerologie Gustave Roussy. F-94800 Villejuif, France
Jean Paul Thiery
Cancer Science Institute of Singapore, National University of Singapore; Institute of Molecular and Cell Biology, A*STAR, Singapore; Department of Biochemistry, National University of Singapore, Singapore

SINOPSIS

Since tumor cell plasticity was first shown to be crucial in tumor promotion and immune surveillance evasion, it has become an issue of intense investigation. Several mechanisms are associated with the acquisition of tumor cell plasticity and immune evasion, including loss of epithelial phenotype through epithelial-to-mesenchymal transition (EMT). We discuss recent evidence revealing that tumor cell plasticity may lead to the emergence of immunoresistant variants and how the tumor microenvironment evolves to shape this plasticity. We argue that targeting carcinoma cell plasticity represents a novel strategy to better control the emergence of resistant variants and to ensure more effective cancer therapies. In this context, the design of innovative integrative immunotherapy approaches is warranted.